RSS feed

Publications (original articles or review articles) published in 2022 from OUS - Section for Cellular Therapy

10 publications found

Abrantes R, Duarte HO, Gomes C, Wälchli S, Reis CA (2022)
CAR-Ts: new perspectives in cancer therapy
FEBS Lett, 596 (4), 403-416
DOI 10.1002/1873-3468.14270, PubMed 34978080

Bajor M, Graczyk-Jarzynka A, Marhelava K, Burdzinska A, Muchowicz A, Goral A, Zhylko A, Soroczynska K, Retecki K, Krawczyk M, Klopotowska M, Pilch Z, Paczek L, Malmberg KJ, Wälchli S, Winiarska M, Zagozdzon R (2022)
PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
J Immunother Cancer, 10 (1)
DOI 10.1136/jitc-2021-002500, PubMed 35078921

Berentzen Å, Brevig T, Hermann R, Ryder T, Winge-Main AK (2022)
Correction: Melanoma - investigation and primary treatment
Tidsskr Nor Laegeforen, 142 (1)
DOI 10.4045/tidsskr.22.0806, PubMed 36655962

Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G (2022)
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
J Transl Med, 20 (1), 419
DOI 10.1186/s12967-022-03624-z, PubMed 36089578

Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM (2022)
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
J Immunother Cancer, 10 (5)
DOI 10.1136/jitc-2021-004345, PubMed 35613827

Forcados C, Joaquina S, Casey NP, Caulier B, Wälchli S (2022)
How CAR T Cells Breathe
Cells, 11 (9)
DOI 10.3390/cells11091454, PubMed 35563759

Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB, Irish JM, Wälchli S, Myklebust JH (2022)
Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression
J Immunol, 209 (10), 2042-2053
DOI 10.4049/jimmunol.2200144, PubMed 36426942

Maggadóttir SM, Kvalheim G, Wernhoff P, Sæbøe-Larssen S, Revheim ME, Josefsen D, Wälchli S, Helland Å, Inderberg EM (2022)
A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
Front Oncol, 12, 1031232
DOI 10.3389/fonc.2022.1031232, PubMed 36439452

Mensali N, Inderberg EM (2022)
Emerging Biomarkers for Immunotherapy in Glioblastoma
Cancers (Basel), 14 (8)
DOI 10.3390/cancers14081940, PubMed 35454848

Silva DN, Chrobok M, Ahlén G, Blomberg P, Sällberg M, Pasetto A (2022)
ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing
Immunooncol Technol, 16, 100099
DOI 10.1016/j.iotech.2022.100099, PubMed 36389443